Results 141 to 150 of about 4,640 (210)
Combined XPO1 Inhibition and Parthenolide Treatment Can Be Efficacious in Treating Triple-Negative Breast Cancer. [PDF]
Int J Mol SciPaulson AL +3 more
europepmc +1 more source
Daraxonrasib in pancreatic cancer: When progress disrupts practice. [PDF]
Drug Discov TodayAzmi AS, Philip PA.
europepmc +1 more source
Beyond Chemoimmunotherapy: Emerging Cellular and Targeted Therapies in Transformed Follicular Lymphoma: A Scoping Review. [PDF]
Cancer ControlAl-Mashdali AF +3 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Expert Opinion on Pharmacotherapy
Selinexor, an XPO1 inhibitor, has emerged as a promising therapeutic option in the challenging landscape of relapsed/refractory multiple myeloma (RRMM).This article provides a review of selinexor, with a focus on available clinical studies involving MM patients and its safety profile.
Ernesto Vigna +2 more
exaly +3 more sources
Selinexor, an XPO1 inhibitor, has emerged as a promising therapeutic option in the challenging landscape of relapsed/refractory multiple myeloma (RRMM).This article provides a review of selinexor, with a focus on available clinical studies involving MM patients and its safety profile.
Ernesto Vigna +2 more
exaly +3 more sources
Selinexor in patients with advanced and recurrent endometrial cancer
Current Problems in Cancer, 2023Selinexor is an oral inhibitor of the nuclear export protein called Exportin 1 (XPO1) with demonstrated antitumor activity in hematological and solid tumors. Selinexor, blocking XPO1, induces nuclear localization of tumor suppressor proteins (including p53, p73, BRCA1, and pRB), leading to the selective induction of apoptosis, and inhibition of DNA ...
Bradley J. Monk +2 more
exaly +3 more sources
Canadian Journal of Health Technologies, 2022
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
openaire +1 more source
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
openaire +1 more source
Selinexor for advanced hematologic malignancies
Leukemia & Lymphoma, 2020Recent measures to classify novel molecular targets with therapeutic potential across multiple hematologic tumors have identified the eukaryotic nuclear exporter, exportin 1 (XPO1), as a promising candidate. Molecular agents termed 'Selective Inhibitors of Nuclear Export' (SINEs) have been developed to selectively inhibit the essential regulatory ...
Janek S. Walker +2 more
openaire +2 more sources
Selinexor for the treatment of multiple myeloma
Expert Opinion on Pharmacotherapy, 2020Introduction: Despite unprecedented advances in the treatment of multiple myeloma (MM), almost all patients develop a disease that is resistant to the five most commonly used and active anti-MM agents. The prognosis for this patient population is particularly poor resulting in an unmet need for additional therapeutic options.
Klaus, Podar +4 more
openaire +2 more sources
The ‘comeback’ of Selinexor: From toxic to tolerable
Current Problems in Cancer, 2022Selinexor is a novel XPO1 inhibitor approved for patients with relapsed refractory multiple myeloma. When used as twice weekly dosing, selinexor is associated with significant toxicities, prohibiting its use in clinical practice. Newer combinations with other chemotherapeutic agents have evaluated less frequent and lower doses of Selinexor with ...
Hamza, Hashmi, Kimberly, Green
openaire +2 more sources
Journal of Clinical Medicine
Background/Objectives: Chimeric antigen receptor T-cell therapy (CAR-T) has become a key treatment option for relapsed/refractory multiple myeloma (RRMM), but factors impairing T-cell fitness may diminish efficacy.
B. Costa +12 more
semanticscholar +1 more source
Background/Objectives: Chimeric antigen receptor T-cell therapy (CAR-T) has become a key treatment option for relapsed/refractory multiple myeloma (RRMM), but factors impairing T-cell fitness may diminish efficacy.
B. Costa +12 more
semanticscholar +1 more source